PURPOSE: Necrotising soft tissue infection (NSTI) is a deadly disease associated with a significant risk of mortality and long-term disability from limb and tissue loss. The aim of this study was to determine the effect of hyperbaric oxygen (HBO(2)) therapy on mortality, complication rate, discharge status/location, hospital length of stay and inflation-adjusted hospitalisation cost in patients with NSTI. METHODS: This was a retrospective study of 45,913 patients in the Nationwide Inpatient Sample (NIS) from 1988 to 2009. RESULTS: A total of 405 patients received HBO(2) therapy. The patients with NSTI who received HBO(2) therapy had a lower mortality (4.5 vs. 9.4 %, p = 0.001). After adjusting for predictors and confounders, patients who received HBO(2) therapy had a statistically significantly lower risk of dying (odds ratio (OR) 0.49, 95 % confidence interval (CI) 0.29-0.83), higher hospitalisation cost (US$52,205 vs. US$45,464, p = 0.02) and longer length of stay (LOS) (14.3 days vs. 10.7 days, p < 0.001). CONCLUSIONS: This retrospective analysis of HBO(2) therapy in NSTI showed that despite the higher hospitalisation cost and longer length of stay, the statistically significant reduction in mortality supports the use of HBO(2) therapy in NSTI.
PURPOSE:Necrotising soft tissue infection (NSTI) is a deadly disease associated with a significant risk of mortality and long-term disability from limb and tissue loss. The aim of this study was to determine the effect of hyperbaric oxygen (HBO(2)) therapy on mortality, complication rate, discharge status/location, hospital length of stay and inflation-adjusted hospitalisation cost in patients with NSTI. METHODS: This was a retrospective study of 45,913 patients in the Nationwide Inpatient Sample (NIS) from 1988 to 2009. RESULTS: A total of 405 patients received HBO(2) therapy. The patients with NSTI who received HBO(2) therapy had a lower mortality (4.5 vs. 9.4 %, p = 0.001). After adjusting for predictors and confounders, patients who received HBO(2) therapy had a statistically significantly lower risk of dying (odds ratio (OR) 0.49, 95 % confidence interval (CI) 0.29-0.83), higher hospitalisation cost (US$52,205 vs. US$45,464, p = 0.02) and longer length of stay (LOS) (14.3 days vs. 10.7 days, p < 0.001). CONCLUSIONS: This retrospective analysis of HBO(2) therapy in NSTI showed that despite the higher hospitalisation cost and longer length of stay, the statistically significant reduction in mortality supports the use of HBO(2) therapy in NSTI.
Authors: Mark E George; Natasha M Rueth; David E Skarda; Jeffery G Chipman; Robert R Quickel; Greg J Beilman Journal: Surg Infect (Larchmt) Date: 2009-02 Impact factor: 2.150
Authors: Massimo Sartelli; Mark A Malangoni; Addison K May; Pierluigi Viale; Lillian S Kao; Fausto Catena; Luca Ansaloni; Ernest E Moore; Fred A Moore; Andrew B Peitzman; Raul Coimbra; Ari Leppaniemi; Yoram Kluger; Walter Biffl; Kaoru Koike; Massimo Girardis; Carlos A Ordonez; Mario Tavola; Miguel Cainzos; Salomone Di Saverio; Gustavo P Fraga; Igor Gerych; Michael D Kelly; Korhan Taviloglu; Imtiaz Wani; Sanjay Marwah; Miklosh Bala; Wagih Ghnnam; Nissar Shaikh; Osvaldo Chiara; Mario Paulo Faro; Gerson Alves Pereira; Carlos Augusto Gomes; Federico Coccolini; Cristian Tranà; Davide Corbella; Pietro Brambillasca; Yunfeng Cui; Helmut A Segovia Lohse; Vladimir Khokha; Kenneth Yy Kok; Suk-Kyung Hong; Kuo-Ching Yuan Journal: World J Emerg Surg Date: 2014-11-18 Impact factor: 5.469
Authors: Massimo Sartelli; Xavier Guirao; Timothy C Hardcastle; Yoram Kluger; Marja A Boermeester; Kemal Raşa; Luca Ansaloni; Federico Coccolini; Philippe Montravers; Fikri M Abu-Zidan; Michele Bartoletti; Matteo Bassetti; Offir Ben-Ishay; Walter L Biffl; Osvaldo Chiara; Massimo Chiarugi; Raul Coimbra; Francesco Giuseppe De Rosa; Belinda De Simone; Salomone Di Saverio; Maddalena Giannella; George Gkiokas; Vladimir Khokha; Francesco M Labricciosa; Ari Leppäniemi; Andrey Litvin; Ernest E Moore; Ionut Negoi; Leonardo Pagani; Maddalena Peghin; Edoardo Picetti; Tadeja Pintar; Guntars Pupelis; Ines Rubio-Perez; Boris Sakakushev; Helmut Segovia-Lohse; Gabriele Sganga; Vishal Shelat; Michael Sugrue; Antonio Tarasconi; Cristian Tranà; Jan Ulrych; Pierluigi Viale; Fausto Catena Journal: World J Emerg Surg Date: 2018-12-14 Impact factor: 5.469
Authors: Massimo Antonelli; Marc Bonten; Maurizio Cecconi; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J R Curtis; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Salvatore M Maggiore; Jordi Mancebo; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2013-01-22 Impact factor: 17.440
Authors: Maximilian Leiblein; Nils Wagner; Elisabeth H Adam; Johannes Frank; Ingo Marzi; Christoph Nau Journal: Orthop Surg Date: 2020-10-04 Impact factor: 2.071